Drug Type TCR therapy |
Synonyms ADP A2M4N7X19, ADP-A2M4N7X19 |
Target |
Mechanism CCL19 modulators(C-C motif chemokine ligand 19 modulators), IL-7 modulators(interleukin 7 modulators), MAGEA4 inhibitors(Melanoma-associated antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 16 May 2022 |